Summit Therapeutics Share Discussion Threads

[chrisatrdg] 26/6/2019 13:25

The reports from the last event are now on the website:

ASM Hub Track: Pharma Pipeline
June 2019
From New Mechanisms to New Standards of Care




SUNDAY - AAR-758
Sunday 23rd June 2019 ASM Microbe San Francisco
In-Vitro Activity of SMT-571 & Comparators Against Clinical Isolates & Reference Strains of Neisseria gonorrhoeae

[chrisatrdg] 21/6/2019 22:36

Summit Therapeutics
Summit Therapeutics
1,055 followers
1d
We'll be presenting at ASM Microbe on our pipeline and strategy for our new classes of #antibiotics. Friday, June 21 from 2:52-3:03pm PDT, Dr. Clive Mason will present on our pipeline and strategy, and on Sunday, June 23 from 10:30am-4:00pm PDT, Dr Paul Meo will present on SMT-571, our new class antibiotic in preclinical development for the treatment of #gonorrhea.

[waterloo01] 20/6/2019 16:52

The more I read the more I think the DISARM act, currently going through Congress might well make all the difference. Just waiting on Trumps signature, so hopefully won't have to wait till 2022.

If the bill gets signed, raising the extra cash will be a great deal easier

[bermudashorts] 20/6/2019 16:38

Thanks gooosed - Ridinilazole trial results seem a long way off but that may be no bad thing! Just have to hope that by 2022 one or some of these incentives have been put into place.

[gooosed] 20/6/2019 16:12

"Existing incentives to entice antibiotic R&D in the United States are too feeble to fix this ‘broken system’ critics have argued. Other parts of the world, such as the UK, are considering different approaches to reinvigorate antibiotic R&D. A UK government report published earlier this year outlined a plan to de-couple price from demand and shift to a more value-based approach that would compel institutions to pay fees based on their need for new antibiotics, akin to a licensing approach that former FDA commissioner Scott Gottlieb threw his support behind."

[kirk 6] 19/6/2019 21:33

Well got my quid in the game with this one ! Hope to see you at next agm

[chrisatrdg] 19/6/2019 21:26

True Kirk 6 That was my impression from today but we have a long wait.

[kirk 6] 19/6/2019 21:07

If the commercialisation of these antibiotics actually happens this could be worth 100's if millions if not more!

[bermudashorts] 19/6/2019 19:49

Thanks both for taking the time and trouble to add your comments

[algernon2] 19/6/2019 19:27

Hi Waterloo and Chris, great to meet you both at last.
I only have a few minor items to add for those interested in the DMD side of things.
Dame Kay Davies is still involved in DMD research and the Utrophin up-regulation side of things.
Summit have no further interest in DMD seeing themselves as an Antibiotic focused Company now.
I did ask if Kay came up with something else in the DMD (utrophin) side of things whether Summit would still have either first refusal or be interested in pursuing it.
The answer unequivocally from Richard Pye was "NO".
So thats it lads the DMD dream is over for us at least.

[chrisatrdg] 19/6/2019 15:51

Hi Waterloo01 Thanks for your excellent posting & good to have met up again.

I am glad I went today & things look bright for the future but it will be a while before we see any further inflection points except where we are post the next funding particularly if it bridges the C-Diff funding gap.

I have no further points to add.

[gooosed] 19/6/2019 15:16

Many thanks Waterloo.

[bermudashorts] 19/6/2019 13:10

Good stuff, thanks Waterloo

[kirk 6] 19/6/2019 13:05

Thanks Waterloo interesting and exciting !

[waterloo01] 19/6/2019 12:56

Quick AGM update.

Lots of talk about the different approach to antibiotics, in going for both superiority and presenting the economic case. Many of the recent failures in the space have a lot to do with the fact most are going for equivalence/me too products.

There are only 8 antibiotics currently in phase 1-3 that are new mechanism if actions, RDZ being one of them

Are about 100 sites currently open (Clinical trials lists 2 but apparently is out of date). Results still planned mid 2021.

Barda relationship is good and possibility of some more from them but there is a funding gap which is estimated to be between $60m and $100m over 2 years.

Most likely this will be raised from equity and one has the feeling they have somethings lined up. Stressed point that last placing was at a premium, so hopefully that's repeated. Dungan continues to be supportive and likely to come in on any further raises.

Push and pull incentives are important, but because of their approach (superiority)they will build an economic case regardless. However the current bill going through US congress (Disarm) could make a massive difference as will pay hospital 102% of the cost of the drug (are other initiatives ongoing as well). Might this be the thing that will change the whole investment environment?

Still suggesting market could be worth $1bn US alone (they want to keep US rights but might other geographies be part of any funding?) and if adopted RDZ should save hospitals $3 bn a year.

Other antibiotics all going to plan.

So in short, an exciting future but further funding needed, but the end prize remains significant and ever more so as and when the investing community start to reinvest in the area (and Disarm act might be the thing that makes the difference here).

More if I remember. Good to meet the other investors.

[chrisatrdg] 18/6/2019 16:05

The Elephant in the room

I think todays RNS may have got rid of 'The Elephant in the room' i.e. future funding & for the first the share price continues to rise (no profit taking).I only wish I had the funds to top up.

[multiplural] 18/6/2019 15:24

BTIG issued a 14 page note on Summit on June 12th . They have a 12 month price target of 5 USD for the ADS or some 80p per share.

[waterloo01] 18/6/2019 15:08

I saw a broker note some time back and they had peak sales of $900m/$1bn, however it's hard to see that given current climate

[kirk 6] 18/6/2019 15:03

What is the likely upside if phase 3 trials are positive? The implications could be monumental with numerous offers of partnerships available to commercialisation!!!The confidence here now must be improving daily

[waterloo01] 18/6/2019 14:59

Nasdaq up nicely from a bottom of $1.20. Market obviously takes comfort that Barda are continuing to fund, with a little extra added on.

[chrisatrdg] 18/6/2019 13:59

Todays RNS

Well looks like my gut feeling Monday was right ( see below) todays RNS is great news & demonstrates that there is additional support for the Phase 3 C-Diff trials which should extend the cash runway.

Monday post:

'Could we be in for a surprise RNS soon in which it is announced that Summit will receive further funding for their C-Diff trials based on recent articles for the need to combat diseases like C-Diff there was a final realisation that their drug must succeed & so funds provided.Just a thought.'

[kirk 6] 18/6/2019 13:19

Sounds very positive!!

[gooosed] 18/6/2019 13:18

"Summit estimates the cost of managing CDI is upwards of US$6bn every year in the US alone."

as per Proactive Investors.

[chrisis33] 18/6/2019 13:07

sounds positive?